期刊文献+

抗ATPase F1α抗体对人非小细胞肺癌血管内皮细胞的抑制作用 被引量:2

Inhibitory effect of ATPase F1αantibody on human non-smaU cell lung cancer-derived vascular endothelial cells
下载PDF
导出
摘要 目的:探讨一种新的抗ATPase F1α抗体,人血管抑制和肿瘤转移相关蛋白(human angiostatin interacting and tumor metastasis involving protein,HAI-TMIP)抗体((MAb3D5AB1,简称GX)对人非小细胞肺癌血管内皮细胞(non-small cell lung cancer-derived vascular endothelial cell,NSCLC-VEC)的抑制作用。方法:从非小细胞肺癌患者手术切除标本分离和原代培养NSCLC-VECs;采用免疫荧光法检测NSCLC-VECs膜上ATPase F1α的表达,RT-PCR分析细胞ATPase FlαmRNA的表达水平;CCK-8法检测GX对NSCLC-VECs增殖的抑制效应,划痕损伤实验检测GX对NSCLC-VECs迁移的抑制作用,FACS检测GX对NSCLC-VECs凋亡的影响。结果:倒置荧光显微镜检测显示,NSCLC-VECs胞膜上有ATPase F1α的显著表达;RT-PCR的结果表明,分别来源于肺腺癌、肺鳞癌的血管内皮细胞中ATPase F1αⅡ肽段基因片段大小为668 bp。CCK-8结果表明,经GX处理,NSCLC-VECs的增殖活力显著低于对照组(P<0.01);划痕损伤实验结果显示,经GX处理的NSCLC-VECs的迁移速度显著低于对照组(P<0.01);FACS结果显示,GX处理后NSCLC-VECs的凋亡率高于对照组(P<0.01)。结论:ATPaseF1α在NSCLC-VECs膜上有较高的表达,GX通过靶向作用于ATPaseF1α抑制NSCLC-VECs的增殖、迁移,并诱导细胞凋亡。 Objective:To investigate the inhibitory effect of human angiostatin interacting and tumor metastasis involving protein (HAI-TMIP) antibody (MAb3DSAB1, GX) ,a new anti-ATPase F1α antibody, against proliferation, migration and apoptosis of non-small cell lung cancer-derived vascular endothelial cells (NSCLC-VECs). Methods: NSCLC- VECs were isolated and cultured from surgical specimens of NSCLC patients. The membrane expression of ATPase F1α in NSCLC-VECs was observed by immunofluorescence means; RT-PCR was used to analyze the expression of ATPase F1α mRNA. CCK-8 assay, wound-healing assay and fluorescence activated cell sorting (FACS) were used to assess the effects of HAI-TMIP antibody on NSCLC-VECs proliferation, migration and apoptosis. Results: ATPase F1α expression was observed in NSCLC-VECs under inverted fluorescent microscope. RT-PCR showed the fragment length of the ATPase F1αⅡ peptide gene derived from pulmonary adenocarcinoma, squamous carcinoma was 668 bp. It was found that the proliferation and migration of NSCLC-VECs were significantly inhibited in HAI-TMIP antibody treated group compared with those in the control group (P 〈 0.01 ) . FACS result showed that the apoptosis rate of and NSCLC-VECs in HAI-TMIP antibody group was significantly higher than that in the control group (P 〈 0.01 ). Conclusion: ATPase F1 α is highly expressed on the membrane of NSCLC-VECs. HAI-TMIP antibody can efficiently inhibit the proliferation and migration of NSCLC-VECs and induce apoptasis through interacting with ATPaseF1α.
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2008年第3期217-222,共6页 Chinese Journal of Cancer Biotherapy
基金 全军医学科研“十一五计划”资助项目(No.01MA159)~~
关键词 非小细胞肺癌 血管内皮细胞 ATP合酶 抗体 靶向治疗 carcinoma, non-small-cell lung vascular endothelial cell ATPase antibody targeted therapy
  • 相关文献

参考文献23

  • 1Cascone T, Gridelli C, Ciardiello F. Combined targeted therapies in non-small cell lung cancer: a winner strategy [ J ]? Curr Opin Oncol,2007,19 ( 2 ) :98-102.
  • 2Gridelli C. Targeted therapies and non-stall cell lung cancer: new developments [ J ]. Curr Opin Oncol,2007,19 ( 2 ) : 75 -77.
  • 3Barinaga. M. A surprising partner for angiostatin [ J]. Science, 1999,283(5409) :1831.
  • 4Burwick NR. , Wahl ML, Fang J, et al. An inhibitor of the F1 subunit of ATP synthase ( IF1 ) modulates the activity of angiostatin on the endothelial cell surface[J]. Biol Chem, 2005,280 ( 3 ) : 1740- 1745.
  • 5彭艳,张霞,王葵,蒋平,焦炳华,倪健.不同转移潜能肝癌细胞株的差异蛋白质组的二维液相色谱分析[J].世界华人消化杂志,2007,15(13):1482-1487. 被引量:7
  • 6Chi SL, Wahl ML, Mowery YM, et al. Angiostatin-like activity of a monoclonal antibody to the catalytic subunit of F1F0 ATP synthase [J]. Cancer Res, 2007, 67(10) : 4716-4724.
  • 7Meintanis S, Thomaidou D, Jessen KR, et al. The neuron-glia signal beta-neuregulin promotes Schwann cell motility via the MAPK pathway[J]. Glia, 2001, 34( 1 ) : 39-51.
  • 8张晓彤,李龙芸,王树兰,穆新林,王孟昭.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,28(3):180-183. 被引量:31
  • 9Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease[Jl. Nat Med,1995, 1 ( 1 ) :27-31.
  • 10Ramalingam S, Belani CP. Recent advances in targeted therapy for non-small cell lung cancer[ J]. Expert Opin Ther Targets, 2007, 11 ( 2 ) : 245-257.

二级参考文献14

  • 1Zhao-You Tang Fan-Xian Sun Jian Tian Sheng-Long Ye Yin-Kun Liu Kang-Da Liu Qiong Xue Jie Chen Jing-Lin Xia Lun-Xiu Qin Hui-Chuan Sun Lu Wang Jian Zhou Yan Li Zeng-Chen Ma Xin-Da Zhou Zhi-Quan Wu Zhi-Ying Lin Bing-Hui Yang Liver Cancer Institute of Fudan University and Zhongshan Hospital,Shanghai 200032,China.Metastatic human hepatocellular carcinoma models in nude mice and cell line with metastatic potential[J].World Journal of Gastroenterology,2001,7(5):597-601. 被引量:34
  • 2Yan Li Zhao-You Tang Sheng-Long Ye Yin-Kun Liu Jie Chen Qiong Xue Jun Chen Dong-Mei Gao Wei-Hua Bao Liver Cancer Institute and Zhongshan Hospital of Fudan University (Former Liver Cancer Institute of Shanghai Medical University),Shanghai 200032,China.Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97[J].World Journal of Gastroenterology,2001,7(5):630-636. 被引量:112
  • 3彭艳,郑颖,蒋平,何玮,侯彦强,周聪,郭春香,倪健,焦炳华.肿瘤细胞蛋白质组的二维液相色谱分离[J].第二军医大学学报,2004,25(8):862-864. 被引量:7
  • 4Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase Ⅲ trials for patients with advanced non-small cell lung cancer: sobering results. J Clin Oncol, 2001, 19: 1734-1742.
  • 5Schiller JH, Harrington D, Belani CP, et al. For the Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med, 2002, 346: 92-98.
  • 6Mill AB, Hoogstrsten B, Staquet M, et al. Reporting results of cancer treatment. Cancer, 1981, 47: 207-214.
  • 7Zhao H, Kanda K. Translation and validation of the standard Chinese version of the EORTC QLQ-C30. Qual Life Res, 2000, 9: 129-137.
  • 8Stephens RJ, Hopwood P, Girling DJ. Defining and analyzing symptom palliation in cancer clinical trials: a deceptively difficult exercise. Br J Cancer, 1999, 79: 538-544.
  • 9Mendelsohn J. Blockade of receptors for growth factors: an anticancer therapy-the fourth annual Joseph H Burchenal American Association for Cancer Research Clinical Reserarsh Award Lecture. Clin Cancer Res, 2000, 6: 747-753.
  • 10Ciardiello F, Caputo R, Pomatico C, et al. Inhibition of growth factor production and angiogenesis in human cancer cell lines by ZD1839 (Iressa), a selective epidermal growth factor tyrosine kinase inhibitor. Clin Cancer Res, 2001, 7: 1459-1465.

共引文献35

同被引文献24

  • 1张晓彤,李龙芸,王树兰,穆新林,王孟昭.吉非替尼治疗晚期非小细胞肺癌疗效观察[J].中华结核和呼吸杂志,2005,28(3):180-183. 被引量:31
  • 2姜扬文,钱莉,蒋桂花,刘伟,龚卫娟,季明春.bcr-abl基因疫苗对小鼠SP2/0/bcr-abl移植瘤的影响[J].中国实验血液学杂志,2006,14(4):800-803. 被引量:7
  • 3陆雪官,LUKA Milas.Satraplatin提高头颈部鳞癌放射治疗疗效的动物实验研究[J].肿瘤,2007,27(3):199-201. 被引量:3
  • 4彭艳,张霞,王葵,蒋平,焦炳华,倪健.不同转移潜能肝癌细胞株的差异蛋白质组的二维液相色谱分析[J].世界华人消化杂志,2007,15(13):1482-1487. 被引量:7
  • 5O' Reilly MS, Holmgren L, Shing Y,et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [J]. Cell, 1994, 79(2) : 315-328.
  • 6Moser TL, Stack MS, Asplin I, et al. Angiostatin binds ATP synthase on the surface of human endothelial ceils [ J ]. Proc Natl Acad Sci U S A, 1999, 96(6) : 2811-2816.
  • 7Das B, Mondragon MO, Sadeghian M,et al. A novel ligand in lymphocyte-mediated cytotoxicity : expression of the beta subunit of H+ transporting ATP synthase on the surface of tumor cell lines [J]. J Exp Med, 1994,180(1): 273-281.
  • 8Chi SL, Pizzo SV. Angiostatin is directly cytotoxic to tumor ceils at low extracellular pH : a mechanism dependent on cell surface-associated ATP synthase [J]. Cancer Res, 2006, 66(2) : 875-882.
  • 9Zhao Y, Zhang W, Kho Y, et al. Proteomic analysis of integral plasma membrane proteins [ J ]. Anal Chem, 2004, 76 (7) : 1817-1823.
  • 10Bae TJ, Kim MS, Kim JW,et al. Lipid raft proteome reveals ATP synthase complex in the cell surface [ J ]. Proteomics, 2004, 4 ( 11 ) : 3536-3548.

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部